Status:
COMPLETED
Risk EValuation And Its Impact on ClinicAL Decision Making and Outcomes in Heart Failure
Lead Sponsor:
Yale University
Conditions:
Heart Failure
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Heart failure is a complex and heterogenous disease with mortality and morbidity that equals more cancers. Numerous studies have examined the ability to improve prognostication from heart failure, ran...
Detailed Description
Heart failure is the major cause of mortality and morbidity in the United States and Western Europe and prognosis in individual patients is highly variable. Quantifying a patient's survival prospects ...
Eligibility Criteria
Inclusion
- Age \>18
- NTproBNP levels of \>500pg/mL within 24 hours of admission
- Intravenous diuretics within 24 hours of admission
Exclusion
- • None
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2021
Estimated Enrollment :
3124 Patients enrolled
Trial Details
Trial ID
NCT03845660
Start Date
January 1 2020
End Date
December 30 2021
Last Update
April 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale New Haven Hospital
New Haven, Connecticut, United States, 06510